Reports Q1 revenue $105.009M, consensus $97.3M. “I am very pleased with our financial results and continued progress on a number of key strategic fronts,” said R. Jeffrey Bailly, Chairman & CEO. “In Q1 we generated 7.4% organic sales growth in both our MedTech and Advanced Components businesses. Operating income and net income grew 24% and 30%, respectively. Our growth in the MedTech space was primarily attributable to an increase in robotic surgery and infection prevention revenue. This more than offset continued softness in other segments such as orthopedics and patient surfaces, where multiple important customers are still taking below-normal levels of product as they work through excess inventory.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UFPT:
- Is UFPT a Buy, Before Earnings?
- UFP Technologies initiated with an Outperform at CJS Securities
- UFP Technologies to Present and Host 1X1 Investor Meetings at the KeyBanc Capital Markets 4th Annual Life Sciences and MedTech Investor Forum
- UFP Technologies announces $500M amended supply agreement with Intuitive Surgical